Investigational drug · Phase 3
INS068
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Type 2 Diabetes.
Phase 3Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
7
Any phase or sponsor naming "INS068"
First trial start
2023
Mar 31, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "INS068", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes
Approved drugs for the same conditions: Type 2 diabetes · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "INS068" as an intervention, largest first.
- To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic DrugsPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05699408 · 513 participants · Start Mar 31, 2023 · Primary completion Nov 23, 2024
Drug: INS068 injection; Insulin Glargine · For: Type 2 Diabetes
Sites: Beijing, China
- A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 DiabetesPivotal-lookingStatus unknown
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05333835 · 455 participants · Start Jul 8, 2022 · Primary completion Mar 30, 2024
Drug: HR17031 injection; INS068 injection and 1 more · For: Type 2 Diabetes
Sites: Beijing, China
- To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.Pivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05702073 · 423 participants · Start Mar 31, 2023 · Primary completion Jun 11, 2024
Drug: INS068 injection; Insulin Glargine · For: Type 2 Diabetes Mellitus
Sites: Shanghai, China
- A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral AntidiabeticsPivotal-lookingCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT04663282 · 179 participants · Start Feb 4, 2021 · Primary completion May 28, 2022
Drug: INS068 injection; Insulin Degludec · For: Type 2 Diabetes
Sites: Huntington Park, California; Lincoln, California; Lomita, California · 35 sites in all
- The Relative Bioavailability of INS068 Injection With Two Different Formulations in Healthy SubjectsCompleted
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05336071 · 24 participants · Start May 12, 2022 · Primary completion May 26, 2022
Drug: INS068 injection; INS068 injection · For: Diabetes Mellitus
Sites: Jinan, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05031871 · 24 participants · Start Sep 2, 2021 · Primary completion Nov 19, 2021
Drug: HR17031 injection ;INS068 injection;SHR20004 injection; HR17031 injection ;INS068 injection;SHR20004 injection and 2 more · For: Type 2 Diabetes Mellitus
Sites: Shanghai, China
Jiangsu HengRui Medicine Co., Ltd.Industry
NCT05887895 · 12 participants · Start May 23, 2023 · Primary completion Jul 18, 2023
Drug: INS062 injection、INS068 injection、HR20014 injection · For: Diabetes
Sites: Hefei, China
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacokinetics and safety of HR17031, a fixed-ratio of INS068/Noiiglutide combination, in Chinese patients with hepatic impairment.
Wang D, Gao X, Mai J, et al. · Diabetes Obes Metab 2026
- Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs.
Tang D, Gao X, Zhu M, et al. · Clin Pharmacokinet 2026
- Efficacy and safety benefits of HR17031, a fixed-ratio combination of INS068 and noiiglutide, versus its components alone in Chinese patients with type 2 diabetes uncontrolled on oral antidiabetic drug(s): A phase 2, multicentre, open-label, randomised, parallel three-arm, treat-to-target trial.
Ji L, Huang D, Lin X, et al. · Diabetes Obes Metab 2025
- Pharmacokinetics and bioavailability of a new long-acting insulin analog in healthy Chinese volunteers: an open, randomized, single-dose, two-period and two-sequence cross-over study.
Chen KG, Zhang YH, Ye PP, et al. · Front Pharmacol 2023
Also in development for Type 2 Diabetes
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
- UBT251Phase 310 trials
The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2
- ZenagamtidePhase 39 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- OlatorepatideHS-20094Phase 38 trials
Jiangsu Hansoh Pharmaceutical Co., Ltd. · Type 2 Diabetes, Overweight or Obesity, Overweight or Obesity Without Diabetes
- CagriSemaCagrilintide B and Semaglutide IPhase 36 trials
Novo Nordisk · Obesity, Diabetes Mellitus, Type 2, Hypertension
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.